• NeuroNode distribution strategy advancing with multiple options for US and global expansion
• NeuroNode US reimbursement coverage expanding to over 70% of population
• NeuroStrip rollout building momentum with growing demand

Control Bionics Ltd has reported its quarterly activities and cash flow report for the period ended 30 September 2025. The company highlighted several key achievements, including advancing its NeuroNode distribution strategy with multiple options for US and global expansion, expanding NeuroNode reimbursement coverage to over 70% of the US population, and building momentum for its NeuroStrip product with growing demand from sports performance and rehabilitation customers. The company reported strong quarterly cash receipts of $1.68 million, up 24% over the previous quarter, and group revenue growth of almost 10% compared to the same period in the prior financial year. Control Bionics also successfully raised $1.5 million through a rights issue and an additional $0.6 million from a placement, strengthening its cash position. The company outlined its strategic focus for FY26, which includes achieving profitability in core markets, scaling the NeuroNode business, expanding the NeuroStrip, accelerating growth through partnerships and acquisitions, and building a high-performance organization to support sustainable long-term growth.

The company expects further improvement in underlying operating cash flows driven by ongoing revenue growth, the conversion to NeuroNode-only distribution model, expansion of SaaS licensing, and increasing commercial activity across its core and emerging markets.

Control Bionics expects to continue its operations and meet its business objectives, supported by continued improvement in revenue performance, diversified income streams, prudent cost management, and additional liquidity secured after year-end. The company believes it would be able to secure additional equity or debt funding if required to support its growth and liquidity needs.